Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics

Werewolf Therapeutics, Inc. (HOWL): $4.69

0.38 (-7.50%)

POWR Rating

Component Grades








Add HOWL to Watchlist
Sign Up

Industry: Biotech




#47 of 360

in industry

HOWL Price/Volume Stats

Current price $4.69 52-week high $8.19
Prev. close $5.07 52-week low $1.57
Day low $4.50 Volume 413,000
Day high $5.08 Avg. volume 243,015
50-day MA $6.27 Dividend yield N/A
200-day MA $3.77 Market Cap 200.44M

HOWL Stock Price Chart Interactive Chart >

Werewolf Therapeutics, Inc. (HOWL) Company Bio

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

HOWL Latest News Stream

Event/Time News Detail
Loading, please wait...

HOWL Latest Social Stream

Loading social stream, please wait...

View Full HOWL Social Stream

Latest HOWL News From Around the Web

Below are the latest news stories about WEREWOLF THERAPEUTICS INC that investors may wish to consider to help them evaluate HOWL as an investment opportunity.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Werewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shareholders would be excited to see that the share price has had a great...

Yahoo | December 14, 2023

Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the most

Key Insights Werewolf Therapeutics' significant private equity firms ownership suggests that the key decisions are...

Yahoo | December 7, 2023

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside c

Yahoo | November 22, 2023

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – – Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide therapeutic index supportive of continued dose escalation – – Additional interim WTX-124 monotherapy data and recommended dose for expansion expected in the first half of 2024 – – Announcing the addition of

Yahoo | November 14, 2023

CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 Earnings

Carvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report.

William White on InvestorPlace | November 3, 2023

Read More 'HOWL' Stories Here

HOWL Price Returns

1-mo -23.24%
3-mo -6.94%
6-mo 93.00%
1-year 82.49%
3-year N/A
5-year N/A
YTD 21.50%
2023 88.29%
2022 -82.79%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!